本帖最后由 老马 于 2013-3-13 13:43 编辑
; I T8 C* r: K8 M7 G: p) K& e
8 A7 J. |* R9 b: {, E/ ~健择（吉西他滨）+顺铂+阿瓦斯汀$ G$ |" b% n( L3 G9 g
Gemzar +Cisplatin + Avastin
+ r U+ N( L, C, Fhttp://annonc.oxfordjournals.org/content/21/9/1804.full
. |7 I$ e6 m8 H' T9 B7 x; ~& U$ A# bOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& K/ v+ G1 v" w1 B JPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - i5 C# e; m+ K) V3 {9 D& s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& ?1 K5 m- X3 g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 275)
* q2 `) O, U+ Z7 m华为网盘附件：& P& G& d( m. N3 E
【华为网盘】ava.JPG) g! ^: c, D* c
|
显身卡
